San Diego, CA—Cosmederm Bioscience has announced that UK-based Woodford Investment Management is investing $50 million into Cosmederm Bioscience.
“We are thrilled about this investment by Woodford Investment Management. It is a testament to our technology platform and the market opportunities that exist in the areas of dermatology and pain management. The capital will allow us to accelerate the growth of our Refinity aesthetic brand, our TriCalm® OTC dermatology brand as well as our drug development programs,” said Cosmederm Bioscience CEO, Sean Edwards.
About Cosmederm Bioscience
Cosmederm Bioscience is a specialty pharmaceutical company focused on dermatology and pain management. The Company currently operates in the areas of aesthetic medicine with its Refinity Skin Science brand and in OTC dermatology with its TriCalm brand. Cosmederm Bioscience is also developing topical prescription drugs targeting inflammatory dermatologic conditions and neuropathic pain. For more information, please visit www.cosmederm.com.
Contact
Cohn & Wolfe for Cosmederm
Devin Kingdon, 323-602-1087
devin.kingdon@cohnwolfe.com